Combination of a CEACAM5-targeting T-cell engager (NILK-2301) with NILK-2401 can either boost NILK-2301 activity (Emax) up to 2.5-fold or allows reaching equal NILK-2301 activity at >600-fold (LS174T) to >3,000-fold (MKN-45) lower doses. NILK-2401 combines promising preclinical activity with limited potential side effects due to the tumor-targeted blockade of CD47 and low immunogenicity and is planned to enter clinical testing.

7 months ago

Journal

CEACAM5 (CEA Cell Adhesion Molecule 5) • SIRPA (Signal Regulatory Protein Alpha)

CEACAM5 positive • CD47 positive

NILK-2301

1year

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. (PubMed, J Hematol Oncol)

In summary, NILK-2301 combines promising preclinical activity and safety with lower probability of ADA-generation due to its format compared to other molecules and is scheduled to enter clinical testing at the end of 2023.

1 year ago

Journal • IO biomarker

CEACAM5 (CEA Cell Adhesion Molecule 5)

CEACAM5 expression • CEACAM5 positive

NILK-2301

over2years

Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer (ESMO 2022)

NILK-2301 + NILK-3301 combination treatment significantly increases activity already at low NILK-2301 doses with reduced cytokine release when given sequentially. IND-filing for NILK-2301 is expected in Q4/2022.

over 2 years ago

IO biomarker

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)

CEACAM5 expression • IL2RA expression • CEACAM5 positive • CD4 expression

NILK-2301 • NILK-3301